Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study

Next Previous
Trial Profile

Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mercaptamine (Primary)
  • Indications Nephropathic cystinosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CYSTADROPS OCT-1
  • Sponsors Orphan Europe

Most Recent Events

  • 25 Aug 2020 According a Recordati Rare Diseases media release, based on the data from a Phase I/II trial a Phase III trial, the U.S. Food and Drug Administration (FDA) has approved CYSTADROPS (cysteamine ophthalmic solution) 0.37% in people living with cystinosis.
  • 08 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top